原文如下:
Nonsteroidal appears safe and effective for noninfectious uveitis
This multinational phase 3 trial enrolled 217 patients with persistent noninfectious intermediate uveitis, posterior uveitis or panuveitis after 2 or more weeks of prednisone treatment. Subjects were randomly assigned to receive adalimumab or placebo every 2 weeks. Patients in the adalimumab group had a lower risk for treatment failure (P<0.001) compared with placebo. Median time to treatment failure was 24 weeks in the adalimumab group compared with 13 weeks in the placebo group. While the rate of adverse events was higher in the adalimumab group, only 6 events in the adalimumab group and 3 in the placebo group were directly attributed to trial intervention.New England Journal of Medicine, September 2016
- See more at: [url]http://www.uveitis.tw/item/2185#sthash.lx9Hc8s1.dpuf